

ACADIA PHARMACEUTICALS INC

Form 4

August 17, 2007

FORM 4**UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549**

Check this box
if no longer
subject to
Section 16.
Form 4 or
Form 5
obligations
may continue.
See Instruction
1(b).

**STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF
SECURITIES**

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934,
Section 17(a) of the Public Utility Holding Company Act of 1935 or Section
30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB
Number: 3235-0287
Expires: January 31,
2005
Estimated average
burden hours per
response... 0.5

(Print or Type Responses)

1. Name and Address of Reporting Person *
Aasen Thomas H

2. Issuer Name **and** Ticker or Trading
Symbol
ACADIA PHARMACEUTICALS
INC [ACAD]

5. Relationship of Reporting Person(s) to
Issuer

(Check all applicable)

(Last) (First) (Middle)
3911 SORRENTO VALLEY
BOULEVARD

3. Date of Earliest Transaction
(Month/Day/Year)
05/09/2007

____ Director ____ 10% Owner
____X____ Officer (give title ____ Other (specify
below) below)
Vice Pres., CFO, Treas. & Sec.

(Street)

4. If Amendment, Date Original
Filed(Month/Day/Year)

6. Individual or Joint/Group Filing(Check
Applicable Line)
____X____ Form filed by One Reporting Person
____ Form filed by More than One Reporting
Person

SAN DIEGO, CA 92121

(City) (State) (Zip)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)	4. Securities Acquired or Disposed of (D) (Instr. 3, 4 and 5)	5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Stock	05/09/2007		G	(A) or (D) D	13,834 (1) \$ 0	2,325 (1)	D
Common Stock	05/09/2007		G	A	\$ 0	26,334	I
Common Stock	08/15/2007		S(2)	D	\$ 15.3	23,334	I
Common Stock	08/15/2007		S(2)	D	\$ 15.45	20,334	I
Common Stock	08/15/2007		S(2)	D	\$ 15.58	16,334	I

Edgar Filing: ACADIA PHARMACEUTICALS INC - Form 4

Common Stock	08/15/2007	S(2)	3,000	D	\$ 15.65	13,334	I	By Family Trust
Common Stock	08/15/2007	S(2)	3,000	D	\$ 15.8	10,334	I	By Family Trust

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

SEC 1474
(9-02)

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned
(e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)	5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4, and 5)	6. Date Exercisable and Expiration Date (Month/Day/Year)	7. Title and Amount of Underlying Securities (Instr. 3 and 4)	8. Price of Derivative Security (Instr. 5)	9. Number of Derivative Securities Beneficially Owned Following Reported Transaction (Instr. 3)
				Code	V (A) (D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Reporting Owners

Reporting Owner Name / Address

Relationships

Director 10% Owner Officer Other

Aasen Thomas H
3911 SORRENTO VALLEY BOULEVARD
SAN DIEGO, CA 92121

Vice Pres., CFO, Treas. & Sec.

Signatures

/s/ Thomas H. Aasen 08/17/2007

Signature of Reporting Person Date

Explanation of Responses:

- * If the form is filed by more than one reporting person, see Instruction 4(b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
- (1) Includes an aggregate of 4,659 shares acquired by the reporting person pursuant to ACADIA's employee stock purchase plan from inception through the date of this filing.

Edgar Filing: ACADIA PHARMACEUTICALS INC - Form 4

The sales reported in this Form 4 were effected pursuant to an existing sales plan established under Rule 10b5-1 of the Securities

- (2) Exchange Act of 1934, as amended. The plan provides for the non-discretionary periodic sales of stock pursuant to predetermined trading parameters that do not permit Mr. Aasen to exercise any subsequent influence over how, when or whether to effect trades under the plan.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *see* Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.